Advanced search
1 file | 1.45 MB Add to list

Targeting neutrophils in asthma : a therapeutic opportunity?

Joyceline De Volder (UGent) , Lars Vereecke (UGent) , Guy Joos (UGent) and Tania Maes (UGent)
Author
Organization
Abstract
Suppression of airway inflammation with inhaled corticosteroids has been the key therapeutic approach for asthma for many years. Identification of inflammatory phenotypes in asthma has moreover led to important breakthroughs, e.g. with specific targeting of the IL-5 pathway as add-on treatment in difficult-to-treat eosinophilic asthma. However, the impact of interfering with the neutrophilic component in asthma is less documented and understood. This review provides an overview of established and recent insights with regard to the role of neutrophils in asthma, focusing on research in humans. We will describe the main drivers of neutrophilic responses in asthma, the heterogeneity in neutrophils and how they could contribute to asthma pathogenesis. Moreover we will describe findings from clinical trials, in which neutrophilic inflammation was targeted. It is clear that neutrophils are important actors in asthma development and play a role in exacerbations. However, more research is required to fully understand how modulation of neutrophil activity could lead to a significant benefit in asthma patients with airway neutrophilia.
Keywords
NECROSIS-FACTOR-ALPHA, CXCR2 ANTAGONIST AZD5069, ADD-ON TREATMENT, AIRWAY INFLAMMATION, DOUBLE-BLIND, P38 MAPK, PERSISTENT ASTHMA, TNF-ALPHA, MONOCLONAL-ANTIBODY, RECEPTOR ANTAGONIST, Asthma, Neutrophilic inflammation

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.45 MB

Citation

Please use this url to cite or link to this publication:

MLA
De Volder, Joyceline, et al. “Targeting Neutrophils in Asthma : A Therapeutic Opportunity?” BIOCHEMICAL PHARMACOLOGY, vol. 182, 2020, doi:10.1016/j.bcp.2020.114292.
APA
De Volder, J., Vereecke, L., Joos, G., & Maes, T. (2020). Targeting neutrophils in asthma : a therapeutic opportunity? BIOCHEMICAL PHARMACOLOGY, 182. https://doi.org/10.1016/j.bcp.2020.114292
Chicago author-date
De Volder, Joyceline, Lars Vereecke, Guy Joos, and Tania Maes. 2020. “Targeting Neutrophils in Asthma : A Therapeutic Opportunity?” BIOCHEMICAL PHARMACOLOGY 182. https://doi.org/10.1016/j.bcp.2020.114292.
Chicago author-date (all authors)
De Volder, Joyceline, Lars Vereecke, Guy Joos, and Tania Maes. 2020. “Targeting Neutrophils in Asthma : A Therapeutic Opportunity?” BIOCHEMICAL PHARMACOLOGY 182. doi:10.1016/j.bcp.2020.114292.
Vancouver
1.
De Volder J, Vereecke L, Joos G, Maes T. Targeting neutrophils in asthma : a therapeutic opportunity? BIOCHEMICAL PHARMACOLOGY. 2020;182.
IEEE
[1]
J. De Volder, L. Vereecke, G. Joos, and T. Maes, “Targeting neutrophils in asthma : a therapeutic opportunity?,” BIOCHEMICAL PHARMACOLOGY, vol. 182, 2020.
@article{8690190,
  abstract     = {{Suppression of airway inflammation with inhaled corticosteroids has been the key therapeutic approach for asthma for many years. Identification of inflammatory phenotypes in asthma has moreover led to important breakthroughs, e.g. with specific targeting of the IL-5 pathway as add-on treatment in difficult-to-treat eosinophilic asthma. However, the impact of interfering with the neutrophilic component in asthma is less documented and understood. This review provides an overview of established and recent insights with regard to the role of neutrophils in asthma, focusing on research in humans. We will describe the main drivers of neutrophilic responses in asthma, the heterogeneity in neutrophils and how they could contribute to asthma pathogenesis. Moreover we will describe findings from clinical trials, in which neutrophilic inflammation was targeted. It is clear that neutrophils are important actors in asthma development and play a role in exacerbations. However, more research is required to fully understand how modulation of neutrophil activity could lead to a significant benefit in asthma patients with airway neutrophilia.}},
  articleno    = {{114292}},
  author       = {{De Volder, Joyceline and Vereecke, Lars and Joos, Guy and Maes, Tania}},
  issn         = {{0006-2952}},
  journal      = {{BIOCHEMICAL PHARMACOLOGY}},
  keywords     = {{NECROSIS-FACTOR-ALPHA,CXCR2 ANTAGONIST AZD5069,ADD-ON TREATMENT,AIRWAY INFLAMMATION,DOUBLE-BLIND,P38 MAPK,PERSISTENT ASTHMA,TNF-ALPHA,MONOCLONAL-ANTIBODY,RECEPTOR ANTAGONIST,Asthma,Neutrophilic inflammation}},
  language     = {{eng}},
  pages        = {{13}},
  title        = {{Targeting neutrophils in asthma : a therapeutic opportunity?}},
  url          = {{http://dx.doi.org/10.1016/j.bcp.2020.114292}},
  volume       = {{182}},
  year         = {{2020}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: